Jones C N, Howard J L, McBennett S T
Psychopharmacology (Berl). 1980 Feb;67(2):111-8. doi: 10.1007/BF00431964.
Various doses of bupropion HCl (Wellbatrin) (5, 10, and 20 mg/kg), a new phenylaminoketone antidepressant, were employed as cues in a two-lever operant discrimination from saline control injections in rats on an FR10 schedule of food reinforcement. Subjects reached and maintained a high level of discrimination in the O vs 20 mg/kg bupropion stimulus condition but not at the lower doses. In generalization testing, the following compounds produced dose-related responding on the bupropion lever: viloxazine, nomifensine, caffeine, d-amphetamine, cocaine, methylphenidate, and benzylpiperazine. Drugs that failed to show dose-related generalization included phenethylamine, thyrotropin-releasing hormone, imipramine, nortriptyline, amitriptyline, desipramine, mianserin, chlordiazepoxide, diazepam, scopolamine, phenobarbital, and morphine. With the important exception of viloxazine, the generalization profile of bupropion seems to reflect its previously reported locomotor stimulant effects in the rat rather than its antidepressant activity and suggests that species differences exist between man and rat with regard to the pharmacologic activity of this new antidepressant.
新型苯氨基酮类抗抑郁药盐酸安非他酮(Wellbatrin)的不同剂量(5、10和20毫克/千克),在大鼠以FR10食物强化程序进行的双杠杆操作性辨别实验中,作为与生理盐水对照注射相区分的线索。在0与20毫克/千克安非他酮刺激条件下,实验对象达到并维持了较高的辨别水平,但在较低剂量时则未达到。在泛化测试中,以下化合物在安非他酮杠杆上产生了剂量相关反应:维洛沙嗪、诺米芬辛、咖啡因、右旋苯丙胺、可卡因、哌甲酯和苄基哌嗪。未能显示出剂量相关泛化的药物包括苯乙胺、促甲状腺激素释放激素、丙咪嗪、去甲替林、阿米替林、地昔帕明、米安色林、氯氮卓、地西泮、东莨菪碱、苯巴比妥和吗啡。除维洛沙嗪这一重要例外,安非他酮的泛化特征似乎反映了其先前报道的对大鼠的运动兴奋作用,而非其抗抑郁活性,这表明在这种新型抗抑郁药的药理活性方面,人与大鼠之间存在种属差异。